Adherence to ribavirin in chronic hepatitis C patients on antiviral treatment: Results from a randomized controlled trial using real-time medication monitoring - 01/11/16
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Summary |
Background and objective |
Adherence is essential in antiviral therapy for chronic hepatitis C. We investigated the effect of real-time medication monitoring on adherence to ribavirin.
Methods |
In this randomized controlled trial, patients in the intervention group received a medication dispenser that monitored ribavirin intake real-time during 24 weeks PEG-interferon/ribavirin±boceprevir or telaprevir. Patients in the control group received standard-of-care. Adherence was also measured by pill count.
Results |
Seventy-two patients were assigned to either intervention (n=35) or control groups (n=37). Median adherence by pill count was 96% (range: 43%–100%) with 30 (94%) of patients exhibiting≥80% adherence. Perfect adherence (i.e. 100%) was similar in intervention and control groups: 22 (85%) vs. 15 (75%) (P=0.47). Adherences by real-time medication monitoring and by pill count did not correlate (R=0.19, P=0.36). No predictors of poor adherence could be identified. Ribavirin trough levels after 8 weeks (median: 2.4 vs. 2.7mg/L, P=0.30) and 24 weeks (median: 3.0 vs. 3.0mg/L, P=0.69), and virological responses did not differ between intervention and control groups.
Conclusions |
Adherence to ribavirin during PEG-interferon containing therapy in chronic hepatitis C is high. Real-time medication monitoring did not influence adherence to ribavirin, plasma ribavirin levels or virological responses.
Le texte complet de cet article est disponible en PDF.Abbreviations : CHC, SMS, RTMM, HCV, SVR, PEG-interferon, AE, EVR, WBC
Plan
Vol 40 - N° 5
P. 622-630 - novembre 2016 Retour au numéro
Article précédent
- Genetic variants of mannose-binding lectin 2 gene influence progression and prognosis of patients with hepatitis B virus infection in China
- Xing Gu, Qiang Ji, Hao Wang, Mingming Jiang, Juan Yang, Meng Fang, Mengmeng Wang, Chunfang Gao
- Serum immune biomarkers in irritable bowel syndrome
- Seyedmehdi Seyedmirzaee, Mohammad Mahdi Hayatbakhsh, Bizhan Ahmadi, Nadieh Baniasadi, Afshin Mohammad Bagheri Rafsanjani, Amin Reza Nikpoor, Mojgan Mohammadi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?